We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01114373
First Posted: May 3, 2010
Last Update Posted: February 26, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Frederic Rahbari-Oskoui, MD, MSCR, Emory University
Results First Submitted: September 15, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Hypertension
Interventions: Drug: Melatonin
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

79 patients came for screening visit. 39 patients were either screen failures or did not want to pursue the study procedures prior to randomization.

Ultimately 40 patients were randomized. 4 patients dropped out and 36 completed both arms of the study.


Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
39 patients who came for screening visit, did not make it to the randomization phase either because they didn't meet eligibility criteria or they decided not to pursue with the study procedure.

Reporting Groups
  Description
Placebo/Melatonin African American subjects with mild to moderate essential hypertension and an elevated nighttime blood pressure >115 mmHg received 24mg of placebo at bed time for 4 weeks followed by 24 mg time release melatonin at bed time for 4 weeks.
Melatonin/Placebo African American subjects with mild to moderate essential hypertension and an elevated nighttime blood pressure >115 mmHg received 24mg daily of time-released melatonin at bed time for 4 weeks, followed by 24 mg of placebo at bed time for 4 week.

Participant Flow for 2 periods

Period 1:   Intervention 1 (4 Weeks)
    Placebo/Melatonin   Melatonin/Placebo
STARTED   21   19 
COMPLETED   18   19 
NOT COMPLETED   3   0 
Lost to Follow-up                1                0 
Incarceration                1                0 
Terminated by PI after protocol violatio                1                0 

Period 2:   Intervention 2 (4 Weeks)
    Placebo/Melatonin   Melatonin/Placebo
STARTED   18   19 
COMPLETED   18   18 
NOT COMPLETED   0   1 
Lost to Follow-up                0                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
36 subjects completed the entire study.

Reporting Groups
  Description
All Subjects African American subjects with mild to moderate essential hypertension received melatonin or placebo PO for the first 4 weeks then were switched to receive either placebo or melatonin PO therapy for an additional 4 weeks without any wash out period in between.

Baseline Measures
   All Subjects 
Overall Participants Analyzed 
[Units: Participants]
 36 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   36 
>=65 years   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 48.9  (9.9) 
Gender 
[Units: Participants]
 
Female   25 
Male   11 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Nighttime Systolic Blood Pressure (SBP)   [ Time Frame: 4 weeks ]

2.  Primary:   Mean Nighttime Diastolic Blood Pressure (DBP)   [ Time Frame: 4 weeks ]

3.  Secondary:   Mean Nighttime Mean Arterial Pressure (MAP)   [ Time Frame: 4 weeks ]

4.  Secondary:   Mean Nighttime Heart Rate (HR)   [ Time Frame: 4 weeks ]

5.  Secondary:   Mean Daytime Systolic Blood Pressure (SBP)   [ Time Frame: 4 weeks ]

6.  Secondary:   Mean Daytime Diastolic Blood Pressure (DBP)   [ Time Frame: 4 weeks ]

7.  Secondary:   Mean Daytime Mean Arterial Pressure (MAP)   [ Time Frame: 4 weeks ]

8.  Secondary:   Mean Daytime Heart Rate (HR)   [ Time Frame: 4 weeks ]

9.  Secondary:   Urinary Dopamine Excretion Rate   [ Time Frame: 4 weeks ]

10.  Secondary:   Urinary Noradrenaline Excretion Rate   [ Time Frame: 4 weeks ]

11.  Secondary:   Urinary Adrenaline Excretion Rate   [ Time Frame: 4 weeks ]

12.  Secondary:   Plasma E-Selectin   [ Time Frame: 4 weeks ]

13.  Secondary:   Plasma P-Selectin   [ Time Frame: 4 weeks ]

14.  Secondary:   Total Sleep Time   [ Time Frame: 4 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Frederic Rahbari-Oskoui, Associate Professor of Medicine
Organization: Emory University
phone: 404-727-3425
e-mail: frahbar@emory.edu



Responsible Party: Frederic Rahbari-Oskoui, MD, MSCR, Emory University
ClinicalTrials.gov Identifier: NCT01114373     History of Changes
Other Study ID Numbers: IRB00021300a
3R21AT004509-01A2S1 ( U.S. NIH Grant/Contract )
First Submitted: April 29, 2010
First Posted: May 3, 2010
Results First Submitted: September 15, 2015
Results First Posted: December 18, 2015
Last Update Posted: February 26, 2016